Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.56 |
| ▸ | TACR1 | P25103 | 5/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074503 | 0.82 | ALDH1A1 (0.47) | TACR1CYP3A4CYP2C9CYP2C19FAAH | |
| SCHEMBL4459444 | 0.81 | CTSB (0.47) | BCHETACR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13671108 | 0.80 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2C19L3MBTL1USP2 | |
| SCHEMBL4452561 | 0.78 | CASR (0.55) | TACR1CYP3A4CYP2C9CYP2C19FAAH | |
| SCHEMBL2879245 | 0.77 | TACR1 (0.65) | TACR1CYP3A4CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL4456818 | 0.77 | CTSB (0.45) | TACR1CYP3A4CYP2C9CYP2C19USP2 | |
| SCHEMBL4392920 | 0.77 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19MAPK14CTSB | |
| SCHEMBL4456920 | 0.76 | P2RX7 (0.41) | FAAHTRPV1USP2POLBCTSB | |
| SCHEMBL8373378 | 0.76 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19MAPK14CTSB | |
| SCHEMBL7856629 | 0.75 | CYP3A4 (0.48) | BACE1CYP3A4CYP2C9CYP2C19FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132452-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270338-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270338-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270338-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | BCHE 1387/4885TACR1 340/4885BACE1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.